PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
34692475-17	2021	Conclusions: The preliminary data showed that the combination of anlotinib and anti-PD-1 antibodies demonstrated promising durable antitumor efficacy with acceptable toxicity in patients with various advance tumors, and promoted favorable changes in serum IL-2, IL-4, IL-10, TNF-alpha, IFN-gamma levels and circulating immune cell subsets in clinical responders.	anlotinib	65-74	interferon gamma	Homo sapiens	286-295	
35568074-6	2022	Interestingly, Anlotinib combined with PD-L1 blockade increased the infiltration of IFN-gamma+CD8+ T cells and natural killer (NK) cells, also decreased the quantity of Treg cells and MDSCs in vivo.	anlotinib	15-24	interferon gamma	Homo sapiens	84-93